Date: 2016-10-20
Type of information: Collaboration agreement
Compound: adeno-associated virus (AAV) vectors
Company: Spark Therapeutics (USA - PA) University of Massachusetts Medical School (USA - MA)
Therapeutic area: Ophtalmological diseases - Hepatic diseases - Liver diseases -CNS diseases
Type agreement: collaboration R&D
Action mechanism: gene therapy
Disease:
Details: * On October 20, 2016, Spark Therapeutics announced a multi-year research agreement with Guangping Gao, Ph.D., the Penelope Booth Rockwell Chair in Biomedical Research, director of the Horae Gene Therapy Center, and professor of microbiology and physiological systems at the University of Massachusetts Medical School. Dr. Gao will collaborate broadly with Spark Therapeutics to identify adeno-associated virus (AAV) vectors from a proprietary library of AAV capsids and evaluate their efficacy, with the goal of enhancing the efficiency of gene delivery to cells in the retina, liver and central nervous system. Under the agreement, Spark Therapeutics has the option to an exclusive, world-wide license for the intellectual property developed under the research agreement.
Financial terms:
Latest news:
